Pfizer's Oral GLP-1 Pill Causes Significant Weight Loss, But Most People Can't Tolerate It
Pfizer's oral GLP-1 drug danuglipron produced up to 12.9% weight loss versus placebo, but 38% of participants dropped out due to side effects — mostly nausea and vomiting.
Quick Facts
What This Study Found
Pfizer's oral GLP-1 drug danuglipron produced statistically significant weight loss in adults with obesity — ranging from 5.0% to 12.9% beyond placebo depending on dose — over 26 to 32 weeks. However, the trial was marred by very high dropout rates: only 39.3% of participants completed treatment, with approximately 38% discontinuing due to adverse events (primarily nausea and vomiting).
The weight loss was dose-dependent, with higher doses producing more weight loss but also more GI side effects. The drug was given twice daily at doses from 40 to 200 mg, escalated over 1, 2, or 4 weeks. While the efficacy signal was clear, the tolerability problem was worse than expected across all treatment groups.
Key Numbers
n=628 · 536 danuglipron + 90 placebo · Weight loss: -5.0% to -12.9% vs placebo · 39.3% completed treatment · ~38% discontinued for AEs · 40–200 mg BID · 26–32 weeks
How They Did This
Randomized, double-blind, placebo-controlled Phase 2b dose-ranging study. 628 adults (ages 18–75) with obesity but without diabetes were randomized to various danuglipron doses (40–200 mg twice daily) or placebo for 26 or 32 weeks. Doses were escalated over 1, 2, or 4 weeks. Primary endpoint was percentage change in body weight from baseline.
Why This Research Matters
The GLP-1 weight-loss market is dominated by injectable drugs like semaglutide and tirzepatide. An effective oral GLP-1 pill could dramatically expand access — no injections, no refrigeration, easier to prescribe. Danuglipron showed the efficacy is there (up to 12.9% weight loss beyond placebo), but the 38% dropout rate from side effects is a major red flag. This tolerability challenge is the central obstacle Pfizer must solve to compete in the oral GLP-1 space.
The Bigger Picture
The race for an effective oral GLP-1 weight-loss pill is one of the highest-stakes competitions in pharma. Novo Nordisk has oral semaglutide (Rybelsus), but its weight-loss efficacy in pill form lags behind the injectable. Pfizer's danuglipron shows strong efficacy but terrible tolerability. This Phase 2b data suggests Pfizer needs significant formulation improvements before danuglipron can compete. The company has been developing a modified-release version to reduce GI side effects — the success of that reformulation will determine danuglipron's future.
What This Study Doesn't Tell Us
The 60.7% discontinuation rate (38% from adverse events alone) severely undermines the reliability of efficacy estimates — participants who tolerated the drug may not represent the broader patient population. Twice-daily dosing is a compliance burden compared to once-weekly injectable competitors. The study excluded people with diabetes, so results may differ in diabetic populations. The 26–32 week duration is relatively short for a weight-loss drug intended for long-term use.
Questions This Raises
- ?Can Pfizer's modified-release formulation of danuglipron solve the tolerability crisis while maintaining the weight-loss efficacy seen in this trial?
- ?How does danuglipron's weight loss of up to 12.9% compare to injectable semaglutide (~15%) and tirzepatide (~20%) when accounting for the high dropout rate?
- ?Would a once-daily formulation rather than twice-daily dosing improve both compliance and tolerability?
Trust & Context
- Key Stat:
- 38% dropout While danuglipron achieved up to 12.9% weight loss vs placebo, nearly 4 in 10 participants quit the trial due to adverse events — mostly nausea and vomiting
- Evidence Grade:
- This is a well-designed Phase 2b randomized, double-blind, placebo-controlled trial with 628 participants. However, the extremely high discontinuation rate (60.7% overall) limits the reliability of efficacy conclusions and raises serious questions about real-world applicability.
- Study Age:
- Published in 2025 with data from the NCT04707313 trial. This is the most recent large-scale efficacy data for danuglipron in obesity, though Pfizer is developing a modified-release formulation that may address the tolerability issues seen here.
- Original Title:
- Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: A randomized, placebo-controlled, dose-ranging phase 2b study.
- Published In:
- Diabetes, obesity & metabolism, 27(9), 4915-4926 (2025)
- Authors:
- Buckeridge, Clare, Cobain, Sonia, Bays, Harold E(3), Matsuoka, Osamu, Fukushima, Yasushi, Halstead, Patricia, Tsamandouras, Nikolaos, Sherry, Nicole, Gorman, Donal N, Saxena, Aditi R
- Database ID:
- RPEP-10242
Evidence Hierarchy
Frequently Asked Questions
Is danuglipron an alternative to Ozempic or Wegovy?
Not yet. It showed promising weight loss in pill form, but it's not approved and has a serious tolerability problem — 38% of trial participants quit due to nausea and vomiting. Pfizer is working on a reformulated version to address this. If they solve the side effect issue, it could eventually compete as an oral alternative to injectable GLP-1 drugs.
Why is an oral GLP-1 drug such a big deal?
Current GLP-1 weight-loss drugs like semaglutide and tirzepatide require weekly injections, which many people dislike or refuse. An effective pill version would make GLP-1 therapy accessible to far more patients and could be easier for primary care doctors to prescribe without specialized injection training.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-10242APA
Buckeridge, Clare; Cobain, Sonia; Bays, Harold E; Matsuoka, Osamu; Fukushima, Yasushi; Halstead, Patricia; Tsamandouras, Nikolaos; Sherry, Nicole; Gorman, Donal N; Saxena, Aditi R. (2025). Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: A randomized, placebo-controlled, dose-ranging phase 2b study.. Diabetes, obesity & metabolism, 27(9), 4915-4926. https://doi.org/10.1111/dom.16534
MLA
Buckeridge, Clare, et al. "Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: A randomized, placebo-controlled, dose-ranging phase 2b study.." Diabetes, 2025. https://doi.org/10.1111/dom.16534
RethinkPeptides
RethinkPeptides Research Database. "Efficacy and safety of danuglipron (PF-06882961) in adults w..." RPEP-10242. Retrieved from https://rethinkpeptides.com/research/buckeridge-2025-efficacy-and-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.